The folk at Swiss biotech research company Cytos appear to be very busy indeed. Judging by the list of their recent trials.
- 2005, May 18: Alzheimer’s
- 2005, May 14 : Vaccine to treat nicotine addiction
- 2005, May 11: Obesity vaccine
Cytos Biotechnology AG is a public Swiss biotechnology company engaged in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs. Immunodrugs are intended for use in treatment and prevention of common chronic diseases which afflict millions of people worldwide.